证券代码： 300086 证券简称：康芝药业 康芝药业股份有限公司投资者关系活动记录表 编号： 2023-004 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | 现场参观 □ | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 26 日 (周五) 下午 14:30~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长 洪江游 | | 员姓名 | 2、副总裁兼董事会秘书 林德新 | | | 3、财务总监 程鹏飞 | | | 4、证券部负责人兼证代 卢芳梅 | | | 投资者提出的问题及公司回复情况： | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问，近期国家公布将了提高儿童药基本目录的相关文件， | | ...

证券代码：300086 证券简称：康芝药业 公告编号：2023-035 康芝药业股份有限公司 康芝药业股份有限公司 董 事 会 2023 年 5 月 18 日 关于参加"2022 年度海南辖区上市公司业绩说明会"的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者更准确 地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治理水平，海南 证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办"海南辖区投资者网 上集体接待日暨上市公司业绩说明会"活动，活动时间为 2023 年 5 月 26 日 14:30-17:00， 平台登陆地址为：http://rs.p5w.net。 届时，康芝药业股份有限公司(以下简称"公司"）主要高管人员将参加本次活动， 通过网络在线交流形式，就公司 2022 年年报披露、财务数据、公司治理、内部控制、 发展战略、经营状况、现金分红、重大事项、可持续发展等投资者所关心的问题，与投 资者进行"一对多"形式的沟通与交流。欢迎广大投资者踊跃参与。 特此公告。 ...

证券代码：300086 证券简称：康芝药业 康芝药业股份有限公司投资者关系活动记录表 编号： 2023-003 | 投资者 | □特定对象调研 □分析师会议 | | --- | --- | | 关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单 | 通过深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn）参 | | 位名称 | 与公司 2022 年度网上业绩说明会的投资者。 | | 及人员 | | | 姓名 | | | 时间 | 2023 年 5 月 15 日 15:00-17：00 | | 地点 | 深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn） | | 上市公 | 1.总裁 洪江涛 | | 司接待 | 2.副总裁兼董事会秘书 林德新 | | 人员姓 | 3.财务总监 程鹏飞 | | 名 | 4.独立董事 郑欢雪 | | | 问 1：去年公司经营情况如此差，公司层面有没有人负责？ | | | 回复： | | | 公司的主营核心业 ...

康芝药业股份有限公司(以下简称"公司")2022 年年度报告及其摘要已于 2023 年 4 月 24 日刊登于巨潮资讯网（http://www.cninfo.com.cn）。 为使投资者更全面地了解公司 2022 年年度报告的内容，公司定于 2023 年 5 月 15 日（星期一）15:00-17:00 举行 2022 年度网上业绩说明会，本次年度业绩 说明会将通过深圳证券交易所提供的"互动易"平台举行，投资者可登录"互动 易"网站（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次年度业 绩说明会。 出席本次说明会的人员有：公司总裁洪江涛先生、独立董事郑欢雪先生、副 总裁兼董事会秘书林德新先生及财务总监程鹏飞先生。 为充分尊重投资者、提升交流的针对性，现就公司本次年度业绩说明会提前 向 投 资 者 公 开 征 集 问 题 。 投 资 者 可 提 前 登 录 " 互 动 易 " 网 站 （http://irm.cninfo.com.cn）进入公司本次年度业绩说明会页面进行提问。公 司将在业绩说明会上对投资者普遍关注的问题进行回答。 公司 2022 年度网上业绩说明会相关活动咨询电话 ...

Financial Performance - The company's revenue for Q1 2023 was ¥174,602,090.13, representing a 58.81% increase compared to ¥109,945,844.25 in the same period last year[4] - Net profit attributable to shareholders was ¥15,414,673.27, a significant turnaround from a loss of ¥46,239,789.41, marking a 133.34% increase[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥13,669,875.91, up 127.64% from a loss of ¥49,455,947.08 in the previous year[4] - Basic earnings per share increased to ¥0.0343, compared to a loss of ¥0.1028 in the same period last year, reflecting a 133.37% improvement[4] - Diluted earnings per share also rose to ¥0.0343, a 133.37% increase from the previous year's loss of ¥0.1028[7] - The net profit for the period was ¥14,274,902.16, a turnaround from a net loss of ¥47,321,037.01 in the same period last year[23] - The total comprehensive income for the period was ¥14,274,902.16, contrasting with a comprehensive loss of ¥47,321,037.01 in the prior year[23] Cash Flow and Assets - The net cash flow from operating activities improved to -¥26,187,505.67, a 40.08% reduction in losses compared to -¥43,702,923.47 in the same period last year[4] - Cash inflow from operating activities totaled 146,784,213.28, compared to 143,161,131.71 in the previous period, reflecting a year-over-year increase of approximately 2.3%[26] - Cash outflow from operating activities decreased to 172,971,718.95 from 186,864,055.18, showing a reduction of about 7.4%[26] - The net cash flow from investing activities was 9,984,189.18, a significant improvement from -35,299,406.40 in the previous period[27] - The ending cash and cash equivalents balance was 179,523,081.44, an increase from 149,938,449.78 in the previous period[27] - The company’s cash and cash equivalents decreased by 90,288,259.66 during the period, compared to a decrease of 99,138,865.45 in the previous period[27] - Total assets at the end of the reporting period were ¥2,149,038,051.81, down 8.91% from ¥2,359,300,615.33 at the end of the previous year[4] - Total current assets decreased to ¥568.52 million from ¥670.46 million, reflecting a decline of about 15.2%[15] Liabilities and Equity - Total liabilities decreased from ¥932,963,148.62 to ¥779,254,536.87, a reduction of about 16.4%[19] - Shareholders' equity attributable to shareholders decreased to ¥1,331,597,779.09, an 8.65% decline from ¥1,457,709,429.86 at the end of the previous year[4] - The company's equity attributable to shareholders increased to ¥1,331,597,779.09 from ¥1,316,183,105.82, showing a growth of approximately 1.2%[19] Operational Highlights - The increase in revenue and profit was primarily driven by a significant rise in pharmaceutical sales due to market recovery[6] - The company reported a government subsidy of ¥2,145,400.82, which positively impacted the financial results[5] - The company successfully held a strategic seminar with China National Pharmaceutical Group, focusing on collaboration opportunities in the Hainan Free Trade Port[12] - The company was recognized as a "High-tech Enterprise" in Hebei Province, enhancing its credibility in technology research and development[13] - The company reported successful entry into a key technology research project for children's oral medication, indicating progress in R&D efforts[13] - The company signed a strategic cooperation agreement with International Universal (Indonesia) Group, aiming to expand its market presence[12] - The company plans to explore diversified cooperation channels and models for high-quality development with local government entities[13] Inventory and Receivables - Accounts receivable decreased to ¥50.09 million from ¥71.13 million, a reduction of about 29.5%[15] - Inventory increased significantly to ¥222.69 million, up from ¥170.40 million, marking an increase of approximately 30.6%[15] Research and Development - Research and development expenses were reported at ¥4,135,560.53, slightly down from ¥4,262,780.66, indicating a decrease of about 3.0%[21] Shareholder Actions - The company announced a shareholder reduction plan, with a significant portion of shares being reduced by over 1%[11]

Financial Performance - The company's revenue was significantly impacted due to the expiration of certain agency products and the exclusion of the original Kangzhi Hospital business from the consolidated financial statements, alongside macroeconomic factors affecting product sales[4]. - The company reported no significant adverse changes in its main business, core competitiveness, or key financial indicators, which remain consistent with industry trends[5]. - The company’s operating revenue for 2022 was ¥535,745,365.83, a decrease of 35.96% compared to ¥836,565,805.56 in 2021[28]. - The net profit attributable to shareholders was -¥187,584,710.74, representing a decline of 1,807.25% from a profit of ¥10,987,504.99 in 2021[28]. - The total assets at the end of 2022 were ¥2,288,471,761.40, a decrease of 6.93% from ¥2,458,781,654.13 at the end of 2021[28]. - The company reported a basic earnings per share of -¥0.4169, down 1,808.61% from ¥0.0244 in 2021[28]. - The weighted average return on equity was -13.30%, a decline of 14.03% compared to 0.73% in 2021[28]. - The company experienced a significant increase in government subsidies, totaling ¥6,452,258.92 in 2022, compared to ¥3,132,012.92 in 2021[34]. - The total liabilities decreased by 12.48% to ¥1,316,183,105.82 at the end of 2022 from ¥1,503,949,219.27 at the end of 2021[28]. - The company reported a significant drop in medical services revenue, which fell to zero from ¥163,309,239.25, marking a 100% decline[90]. Research and Development - The company has established a national-level postdoctoral research station dedicated to pediatric medication, enhancing its research capabilities[48]. - The company has a total of 51 patents in China, including 48 invention and utility model patents, and 3 design patents, with 7 invention patents currently under application[52]. - R&D expenses increased by 93.42% to ¥28,442,453.02, reflecting a commitment to enhancing product development[101]. - The company increased its R&D personnel from 110 in 2021 to 134 in 2022, representing a growth of 21.82%[104]. - The company plans to enrich its product line with new products currently in clinical research, including Ibuprofen Deoxycorticosterone Tablets and Children's Dextromethorphan Hydrobromide Membrane[102]. - The company has entered the registration process for 7 pharmaceutical R&D projects, with 3 projects, including the Children's Dextromethorphan Hydrobromide Film and Injectable Suramin Sodium, currently undergoing clinical research[81]. - The company has successfully completed Phase I clinical trials for the injectable Suramin sodium and has received Phase II clinical trial approval for its new indication in treating acute kidney injury[135]. Market Position and Strategy - The company is positioned as a leading domestic enterprise in children's health, with a focus on specialized and large-scale production of pediatric medications[44]. - The company is actively expanding its market presence in the pediatric medication sector, driven by the increasing recognition of specialized treatments for pediatric diseases[44]. - The pharmaceutical industry in China is expected to continue growing, with a projected compound annual growth rate of 5.19% from 2014 to 2021[38]. - The company aims to focus on children's health products, including children's medicine, healthcare products, and medical protection supplies, as part of its strategic development[148]. - The company plans to enhance its operational efficiency and profitability by implementing cost reduction measures and improving asset utilization[150]. - The company is committed to expanding its new drug research and development, particularly in pediatric medicine and complex generics, to strengthen its product pipeline for the next decade[150]. Governance and Compliance - The company has established a governance structure that ensures clear responsibilities, effective checks and balances, and risk prevention, aligning with regulatory requirements[162]. - The board of directors consists of 7 members, including 3 independent directors, meeting the legal and regulatory requirements[164]. - The company has implemented a comprehensive information disclosure management system to ensure timely and accurate communication with investors[166]. - The company maintains an independent financial accounting system and has not faced any regulatory interventions during the reporting period[162]. - The company has a strong governance structure with no conflicts of interest among its key personnel[189]. - The company has not faced any penalties from the China Securities Regulatory Commission or other relevant departments in the past five years, nor has it been subject to any disciplinary actions from the stock exchange[178]. Operational Challenges and Risks - The company is facing risks from intensified industry competition and plans to implement measures to mitigate these risks[152]. - The average profit margin in the pharmaceutical industry is declining, influenced by national policies such as centralized procurement and price controls, which may pressure the company's product pricing[154]. - Environmental protection regulations are becoming stricter, potentially increasing the company's operational costs related to compliance[156]. - Foreign exchange fluctuations pose a risk to the company's import and export pricing, which could affect competitiveness and profitability[156]. - Management complexity is increasing due to company expansion and acquisitions, necessitating a focus on optimizing control models and enhancing operational efficiency[156]. Product Development and Innovation - The company has established a strong research and development matrix in collaboration with high-end research centers, including Guangdong Pharmaceutical University and South China University of Technology[51]. - The company has a strong focus on research and development in the pharmaceutical sector, aiming to enhance its product offerings[174]. - The company is actively involved in market expansion strategies to increase its market share in the pharmaceutical industry[174]. - The company is focusing on improving its environmental management systems to mitigate risks associated with environmental regulations[156]. Financial Management - The company is committed to improving its financial management and risk control to ensure sustainable and stable development[151]. - The company has a strategic focus on investor relations and compliance with regulatory requirements to foster transparency and trust with stakeholders[196]. - The company has maintained a stable shareholding structure with no significant changes in the number of shares held by existing directors and executives[175].

证券代码：300086 证券简称：康芝药业 海南康芝药业股份有限公司投资者关系活动记录表 编号：2015-002 1 | --- | --- | --- | |-----------------------------|-------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 融通基金管理有限公司 朱丹；宝盈基金管理有限公司 李健 | | 人员姓名 | 伟；金鹰基金管理有限公司 方超 | | | 时间 | 2015-5-8 | | | 地点 | 广州 | | | 上市公司接待人 | | 副总裁李幽泉先生、副总裁兼董事会秘书林德新先生 | | 员姓名 | | | | 投资者关系活动 主要内容介绍 | 了解公司 ...

证券代码：300086 证券简称：康芝药业 编号：2015-001 | --- | --- | --- | |-----------------------------|-------------------------------------------------------|---------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 国信证券股份有限公司 林帅；深圳卓逸财富投资有限公司 | 冯雪敏；广东新价值投资有限公司 孙宗胜；广东瑞天投资管 | | 人员姓名 | 理有限公司 | 龚继海；广东西域投资管理有限公司:张磊。 | | 时间 | 2015-5-7 | | | 地点 | 广州 | | | 上市公司接待人 员姓名 | | 副总裁李幽泉先生、副总裁兼董事会秘 ...

证券代码: 300086 证券简称: 康芝药业 海南康芝药业股份有限公司投资者关系活动记录表 编号: 2015-004 | --- | --- | --- | --- | |------------------------------|-------------------------------------------------------------------------------------------|-----------------------------------------|-------| | 投资者关系 \n活动类别 | 口特定对象调研 \n团媒体采访 \n口新闻发布会 □现场参观 \n口其他 （谐文字说明其他活动内容） | □分析师会议 \n口业绩说明会 \n口路演活动 | | | 参与单位名 称及人员姓名 | 《第一财经日报》黄婷 | | | | | | | | | 时间 | 2015-12-25 | | | | 地点 | 海南康芝药业股份有限公司广州办公区 | | | | 上市公司接 待人员姓名 | 洪江游、方康莉 | | | | 投资者关系 活动主要内 容介绍 | 了解公司 ...